BioCryst Pharmaceuticals Inc BCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
-
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
BioCryst to Present at Upcoming Investor Conferences
-
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
-
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
BioCryst to Report Second Quarter 2024 Financial Results on August 5
Trading Information
- Previous Close Price
- $7.55
- Day Range
- $7.54–7.68
- 52-Week Range
- $4.03–8.88
- Bid/Ask
- $7.00 / $8.15
- Market Cap
- $1.57 Bil
- Volume/Avg
- 1.3 Mil / 2.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.98
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 531
- Website
- https://www.biocryst.com
Comparables
Valuation
|
Metric
|
BCRX
|
02509
|
VXRT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 35.46 | 2.30 |
Price/Sales | 3.98 | 108.80 | 8.49 |
Price/Cash Flow | — | — | — |
Price/Earnings
BCRX
02509
VXRT
Financial Strength
|
Metric
|
BCRX
|
02509
|
VXRT
|
|---|---|---|---|
Quick Ratio | 2.64 | 1.70 | 4.28 |
Current Ratio | 2.82 | 1.86 | 4.54 |
Interest Coverage | −0.61 | −18.42 | −30.10 |
Quick Ratio
BCRX
02509
VXRT
Profitability
|
Metric
|
BCRX
|
02509
|
VXRT
|
|---|---|---|---|
Return on Assets (Normalized) | −27.75% | −47.40% | −61.64% |
Return on Equity (Normalized) | — | −341.08% | −92.00% |
Return on Invested Capital (Normalized) | −14.10% | −56.34% | −71.33% |
Return on Assets
BCRX
02509
VXRT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hpzmbbrvs | Kjxzg | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jpvdfggk | Xyvxp | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dnqhhqj | Dzsht | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Czqwxzx | Ydfylnq | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Cjrjxgxk | Fgdkk | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Kzqtvxtd | Vwly | $28.0 Bil | |||
| Moderna Inc
MRNA
| Hwfknkvl | Cggl | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Hyndtcrxm | Zht | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sktsjcbs | Rwznfq | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mgjfvmxx | Mxthfv | $12.6 Bil |
United States